Omeros Corp (OMER) stock
Close on Nov 11, 2026Market cap $1.31BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.31B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -5.23%
Fundamentals
- Net income
- $124.83M
- EPS, diluted
- -$0.05
- Free cash flow
- -$68.73M
- Book value per share
- -$0.57
- Diluted shares
- 90M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $17.30
- Open
- $17.44
- Day's range
- $17.30 – $18.18
- Volume
- 756,999
- Average volume (20 days)
- 1,143,952
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.85
- 52-week range
- $6.24 – $21.24
- RSI (14 days)
- 52.5
- Volatility (1 year)
- 111.0%
- Relative volume
- 0.48×
- WACC
- 14.1%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | OMER | S&P 500 | Difference | OMER per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.5% | -2.4% | −6.1 pts | ||
| 3 months | +33.5% | -1.2% | +34.6 pts | ||
| Year to date | +5.7% | +12.3% | −6.6 pts | ||
| 1 year | +163.4% | +12.4% | +151.0 pts | ||
| 3 years | +1352.0% | +78.8% | +1273.2 pts | +144.0% | +21.4% |
| 5 years | +121.6% | +75.2% | +46.4 pts | +17.3% | +11.9% |
| 10 years | +43.5% | +311.1% | −267.6 pts | +3.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Omeros filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- News
About Omeros
Pharmaceutical Preparations
Omeros Corporation is a commercial-stage biopharmaceutical company that discovers and develops protein and small-molecule therapeutics for complement-mediated diseases, cancers, and addictive disorders. Its approved commercial product is YARTEMLEA, a MASP-2 inhibitor for stem cell transplant-associated thrombotic microangiopathy. Its development pipeline includes complement inhibitors, PDE7 inhibitors for addiction and movement disorders, oncology candidates for leukemia, and infectious disease therapies. The company's customers are stem cell transplant centers, hospitals, and specialized medical teams treating adult and pediatric patients.
Company profile, executives and historyOmeros stock: common questions
What is Omeros's stock price?
OMER closed at $18.15 on Nov 11, 2026, up 4.91% on the day. Over the past 52 weeks it traded between $6.24 and $21.24.
What is Omeros's market cap?
Omeros was worth $1.31B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is OMER's P/E ratio?
Omeros lost money over fiscal 2025 (diluted EPS -$0.05), so it has no meaningful P/E ratio.
Does Omeros pay a dividend?
No. Omeros has not paid a cash dividend over the last twelve months.
When does Omeros report earnings next?
Omeros is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has OMER stock performed over the past year?
Including dividends, OMER returned +163.4% over the past year, against +12.4% for the S&P 500.
How many OMER shares are sold short?
13M shares were sold short at the latest FINRA report, 18.58% of the float, or 9.6 days of average trading volume.
Who are Omeros's competitors?
Companies most similar to Omeros by business, industry and size include VSTM, AGIO, INSM, KNSA, RIGL.
See a number that looks wrong?